Patents by Inventor Gerd Ruehter

Gerd Ruehter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective FKBP51 ligands for treatment of psychiatric disorders
    Patent number: 10246413
    Abstract: The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 2, 2019
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Steffen Gaali, Felix Hausch, Alexander Kirschner, Xixi Feng, Andreas Bracher, Gerd Ruehter
  • 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
    Patent number: 9962389
    Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: May 8, 2018
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Dirk Kosemund, Philip Lienau, Gerd Rühter, Carsten Schultz-Fademrecht
  • SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20180072667
    Abstract: The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
    Type: Application
    Filed: September 13, 2017
    Publication date: March 15, 2018
    Inventors: Steffen Gaali, Felix Hausch, Alexander Kirschner, Xixi Feng, Andreas Bracher, Gerd Ruehter
  • Selective FKBP51 ligands for treatment of psychiatric disorders
    Patent number: 9845292
    Abstract: The present invention relates to compounds of the general formula (I) having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: December 19, 2017
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Steffen Gaali, Felix Hausch, Alexander Kirschner, Xixi Feng, Andreas Bracher, Gerd Ruehter
  • 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES CONTAINING A SULFOXIMINE GROUP
    Publication number: 20170217949
    Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Ulrich LÜCKING, Rolf BOHLMANN, Arne SCHOLZ, Gerhard SIEMEISTER, Mark Jean GNOTH, Ulf BÖMER, Dirk KOSEMUND, Philip LIENAU, Gerd RÜHTER, Carsten SCHULTZ-FADEMRECHT
  • 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
    Patent number: 9669034
    Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: June 6, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Dirk Kosemund, Philip Lienau, Gerd Rühter, Carsten Schultz-Fademrecht
  • SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20160289184
    Abstract: The present invention relates to compounds of the general formula (I) having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
    Type: Application
    Filed: September 15, 2014
    Publication date: October 6, 2016
    Inventors: Steffen Gaali, Felix Hausch, Alexander Kirschner, Xixi Feng, Andreas Bracher, Gerd Ruehter
  • Pharmaceutically active disubstituted pyridine derivatives
    Patent number: 9242937
    Abstract: The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: January 26, 2016
    Assignees: Bayer Intellectual Property GmbH, LEAD DISCOVERY CENTER GMBH
    Inventors: Gerd Rühter, Peter Nussbaumer, Axel Choidas, Carsten Schulz-Fademrecht, Bert Klebl, Jan Eickhoff
  • Pharmaceutically active disubstituted triazine derivatives
    Patent number: 9226929
    Abstract: The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: January 5, 2016
    Assignee: Bayer Intellectual Property GMBH
    Inventors: Gerd Rühter, Uwe Koch, Peter Nussbaumer, Carsten Schulz-Fademrecht, Jan Eickhoff
  • Pharmaceutically active pyrazolo-triazine derivatives
    Patent number: 9096608
    Abstract: Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: August 4, 2015
    Assignee: Lead Discovery Center GmbH
    Inventors: Jan Eickhoff, Gunther Zischinsky, Uwe Koch, Gerd Rühter, Carsten Schultz-Fademrecht, Peter Nussbaumer
  • PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES
    Publication number: 20150111873
    Abstract: Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.
    Type: Application
    Filed: March 1, 2013
    Publication date: April 23, 2015
    Applicant: LEAD DISCOVERY CENTER GMBH
    Inventors: Jan Eickhoff, Gunther Zischinsky, Uwe Koch, Gerd Rühter, Carsten Schultz-Fademrecht, Peter Nussbaumer
  • Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines
    Patent number: 8916557
    Abstract: The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: December 23, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Gerd Rühter, Carsten Schultz-Fademrecht, Dirk Kosemund, Philip Lienau
  • 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES CONTAINING A SULFOXIMINE GROUP
    Publication number: 20140315906
    Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).
    Type: Application
    Filed: May 21, 2012
    Publication date: October 23, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Dirk Kosemund, Philip Lienau, Gerd Rühter, Carsten Schultz-Fademrecht
  • Pharmaceutically Active Disubstituted Pyridine Derivatives
    Publication number: 20140296304
    Abstract: The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase.
    Type: Application
    Filed: March 1, 2012
    Publication date: October 2, 2014
    Applicants: LEAD DISCOVERY CENTER GMBH, BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Gerd Rühter, Peter Nussbaumer, Axel Choidas, Carsten Schulz-Fademrecht, Bert Klebl, Jan Eickhoff
  • PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES
    Publication number: 20140179662
    Abstract: The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase.
    Type: Application
    Filed: March 1, 2012
    Publication date: June 26, 2014
    Applicants: LEAD DISCOVERY CENTER GMBH, BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Gerd Rühter, Uwe Koch, Peter Nussbaumer, Carsten Schulz-Fademrecht, Jan Eickhoff
  • SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES
    Publication number: 20140045852
    Abstract: The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: April 18, 2012
    Publication date: February 13, 2014
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bomer, Gerd Rühter, Carsten Schultz-Fademrecht, Dirk Kosemund, Philip Lienau
  • ?adrenergic agonists
    Patent number: 7265127
    Abstract: The present invention relates to 2-imidazo[1,2-a]pyridine group containing ?3 adrenergic receptor agonists or pharmaceutical salts thereof.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: September 4, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten
  • ?adrenergic agonists
    Patent number: 7253181
    Abstract: The present invention relates to pyrrolopyridine-3-yl group containing ?3 adrenergic receptor agonists or pharmaceutical salts thereof.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: August 7, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten
  • ?adrenergic agonists
    Patent number: 7241772
    Abstract: The present invention relates to 2-imidazo[1,5-a]pyridine containing ?3 adrenergic receptor agonists or pharmaceutical salts thereof.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: July 10, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten
  • 3-Substituted oxindole ?3 agonists
    Patent number: 7205407
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of Formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: April 17, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten